WOAH Reference Laboratory annual reports (RINDERPEST)

Activities in 2024						
Name (including Title) of Head of Laboratory (Responsible Official): Dr. Nathalie Vachiery						
Name (including	Name (including Title and Position) of WOAH Reference Expert: Dr. Arnaud Bataille					
Email address:	arnaud	d.bataille@cirad.fr				
Address of labo	Address of laboratory: Campus International de Baillarguet TA A-15/G 34398 Montpellier Cedex 5 FRANCE					
Website:	e: https://umr-astre.cirad.fr/					
Telephone:	+33 4 67 5	59 39 04	Fax:			

A: Maintaining Scientific and Technical Skills

- 1. Did your laboratory perform relevant diagnostic tests for purposes such as disease, diagnosis, screening of animals for export, surveillance, etc. (not for quality control, proficiency testing or staff training)
 - a. For the specified disease?
 - b. For closely related diseases or pathogens?

Disease	Diagnostic Tost	Indicated in WOAH	Total number of tests performed last year		
Disease	Diagnostic Test	Manual (Yes/No)	Nationally	Internationally	
Rinderpest	Seroneutralisation test	Yes	20		
Rinderpest	RT-PCR	Yes		5	
Rinderpest	Vaccine sterility test	Yes	7		
PPR (see report of WOAH ref lab for PPR)					

2. Did your laboratory produce, supply, or import standard reference reagents officially recognised by the WOAH for the specified disease or for closely related diseases?

Type of Reagent Available	Related diagnostic test	Produced/Supplied/Imported	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	Name of recipient WOAH member countries

3. Did your laboratory supply, exchange or receive standard reference reagents and/or other diagnostic reagents for the specified disease

Type of reagent	Related diagnostic test	Supplied by your lab, exchanged or received	Amount	Name of recipient or supplier member country

4. Did your laboratory provide expert advice in technical consultancies on the request of an WOAH Member Country for the specified disease or for closely related diseases?

Name of the WOAH member country receiving the technical consultancy	Purpose	How the advice was provided
WOAH	Revision of WOAH terrestrial manual chapter on Rinderpest	Revision of document with expert groups, email exchanges
AU-PANVAC	Production of RPV vaccine bank in collaboration with NVI	Email exchanges, reception of RNA samples for genomic analyses (done in 2025)
PPR (see report of WOAH ref lab for PPR)		

5. What method of dissemination of information is most often used by your laboratory? (please provide information on activities for other diseases relevant to maintaining capability for specified disease) [a: Articles published in peer-reviewed journals; b: International conferences; c: National conferences; d: Other]

contenant-
contenant-
contenant-

7. Did your laboratory implement activities to ensure ongoing capability for the designated disease or closely related disease in the event of loss of the key staff including the WOAH Reference Expert?

Activity	Description
Destruction of all Rinderpest containing material	CIRAD destroyed all its RCVM and is now only category B RHF , holding RPV vaccine seed
Inspection of RHF by WOAH and FAI with independent experts	CIRAD received delegates from WOAH and FAO and independent experts to inspect its facility and confirm its capacity for its role as cat B RHF

B: Laboratory Systems

8.	Does your laboratory have a Quality Management System certified according to an International Standard? If YES indicate the name of the quality management system adopted or currently in place. Also attach a scanned certificate of the system.						
	ISO17025						
9.	Is your laboratory accredited by an internation accreditation body.	onal accreditation body? If 'y	es' indicate test for which your laborat	ory is accredited and name of the			
	ELISA and PCR, COFRAC						
10.	Does your laboratory maintain a "biorisk man	nagement system" for the pa	athogen and the disease concerned?				
	x Yes	☐ No					
11.	Does your laboratory have a biosecurity system	em in place to ensure securit	ry for the pathogen and materials that	may contain the infectious pathogen?			
	x Yes	☐ No					
		C: Capability to Res	pond to a Suspected Case				
12.	In the last year, did your laboratory perform	diagnostic tests for the spec	ified pathogen and the disease in order	to confirm ongoing capability?			
	Diagnostic Test		Indicated in WOAH Manual (Yes/No)	Total number of tests performed last year			

13.	Did	our laboratory	produce	vaccines t	for the s	pecified	disease o	r similar	diseases?	?
-----	-----	----------------	---------	------------	-----------	----------	-----------	-----------	-----------	---

Disease	Amount supplied nationally or internationally

14. Did your laboratory organise or participate in inter-laboratory proficiency tests with any other laboratories for the specified disease or similar diseases?

Role of your laboratory (organiser or participant)	Disease	Test	Number of participating laboratories	Regions of participating WOAH member countries
	PPR (see report of WOAH ref lab for PPR)			

D: Networks and Linkages

15. Did your laboratory organise or participate in scientific meetings for the specified disease?

Title of event	Date	Location	Role (Organiser, speaker, presenter)	Title of work presented
FAO Global Conference on Animal Health Innovation, Reference Centres, and Vaccines (RCVI)	from 23 to 25 September 2024	Rome	None concerning RPV	-

16. Did your laboratory exchange information with other WOAH Reference Laboratories designated for the same pathogen or disease?

	x Yes	☐ No						
17.	Was your laboratory involved in maintaining a network with WOAH Reference Laboratories designated for the same pathogen or disease?							
	☐ Yes	x No						
18.	Did your laboratory place expert consultants at the disposal of the WOAH?							
	x Yes	☐ No						
19.	9. Did your laboratory carry out activities to raise awareness and improve capability for this disease in other member countries?							
	Description of activity		Date	Member countries				
E: Biosafety								
20.	What level of biocontainment is used in your laboratory for (a) storage and (b) handling of potentially infectious material for the specified disease?							
	BSL-3, with storage of material in locked safe	-3, with storage of material in locked safes (no infectious material kept at the moment)						
21.	Does your laboratory maintain a structured ris	k assessment for work witl	n potentially infectious materia	Il for the specified disease?				
	x Yes	☐ No						

22.	22. Was your laboratory's risk assessment for work with potentially infectious material reviewed in the past year?						
	x Yes		□No				
23.	23. Does your laboratory have an emergency response plan for biosafety incidents involving potentially infectious material for the specified disease?						
	x Yes		□No				
			F: Research				
24. Did your laboratory develop new diagnostic methods for the designated pathogen or disease, or a similar disease?							
	Disease		Diagnostic Method		Description		
PF	PPR (see report of WOAH ref lab for PPR)						
25. Did your laboratory participate in international scientific studies in collaboration with WOAH Member Countries other than your own?							
	Title of study	Duration	Purpose of study	Partne	ers (Institutions)	WOAH Member Countries Involved other than your Country	
	· ·		!				
26.	Did your laboratory collaborate with o the pathogen of interest or a similar pa		ence Laboratories for the same dise	ease on scier	itific research projects	s for the diagnosis or control of	
26.			ence Laboratories for the same dise Scope	ease on scier		s for the diagnosis or control of WOAH Reference Laboratories	
Se fro	the pathogen of interest or a similar pa	ollected Suppo		ease on scier		WOAH Reference Laboratories	

27.	27. Additional comments regarding your report (if any):						
	<u> </u>						